Indol-3-yl-tetramethylcyclopropyl ketones: Effects of indole ring substitution on CB2 cannabinoid receptor activity

Journal of Medicinal Chemistry

Volumn 51, Issue 6, 2008, Pages 1904-1912

  Frost, Jennifer M ^a   Dart, Michael J ^a   Tietje, Karin R ^a   Garrison, Tiffany R ^a   Grayson, George K ^a   Daza, Anthony V ^a   El Kouhen, Odile F ^a   Miller, Loan N ^a   Li, Lanlan ^a   Yao, Betty B ^a   Hsieh, Gin C ^a   Pai, Madhavi ^a   Zhu, Chang Z ^a   Chandran, Prasant ^a   Meyer, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[1 (2 MORPHOLIN 4 YLETHYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE 4 TOLUENESULFONIC ACID; [1 (TETRAHYDRO 2H PYRAN 4 YLMETHYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; [5 (BENZYLOXY) 1 (2 MORPHOLINOETHYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; [5 HYDROXY 1 (2 MORPHOLIN 4 YLETHYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; [5 HYDROXY 1 (2 MORPHOLINOETHYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; [6 (BENZYLOXY) 1 (TETRAHYDRO 2H PYRAN 4 YLMETHYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; [6 HYDROXY 1 (TETRAHYDRO 2H PYRAN 4 YLMETHYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; [6 METHOXY 1 (TETRAHYDRO 2H PYRAN 4 YLMETHYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; FREUND ADJUVANT; INDOLE DERIVATIVE; KETONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPERALGESIA; NONHUMAN; RAT; SUBSTITUTION REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING, COMPETITIVE; CELL LINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERALGESIA; INDOLES; KETONES; LIGANDS; MOLECULAR CONFORMATION; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41149157008     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7011613     Document Type: Article

References (54)

1. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Yound, A. C.; Bonner, T. I. Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA. Nature 1990, 346, 561-564.
2. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 1993, 365, 61-65.
3. (a) Cabral, G. A.; Marciano-Cabral, F. Cannabinoid Receptors in Microglia of the Central Nervous System: Immune Functional Relevance. J. Leukocyte Biol. 2005, 78, 1192-1197.
4. (b) Van Sickle, M. D.; Duncan, M.; Kingsley, P. J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J. S.; Marnett, L. J.; Marzo, V. D.; Pittman, Q. J.; Patel, K. D.; Sharkey, K. A. Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science 2005, 310, 329-332.
5. 2 Receptor-Mediated Antihyperalgesia: Possible Direct Involvement of Neural Mechanisms. Eur. J. Neurosci. 2006, 23, 1530-1538.
6. Chapman, V.; Finn, D. P. Analgesic Effects of Cannabinoids: Sites and Mechanisms of Action. Rev. Analg. 2003, 7, 25-39.
7. 2, a Peripheral Cannabinoid Receptor. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14228-14233.
8. 2 Cannabinoid Receptor Agonists: Pain Relief without Psychoactive Effects? Curr. Opin. Pharmacol. 2003, 3, 62-67.
9. 2 Cannabinoid Receptors Are Implicated in Inflammatory Pain. Pain 2002, 96, 253-260.
10. 2 Cannabinoid Receptors. Anesthesiology 2003, 99, 955-960.
11. (a) Flygar, J.; Gustafsson, K.; Kimby, E.; Christensson, B.; Sander, B. Cannabinoid Receptor Ligands Mediate Growth Inhibition and Cell Death in Mantel Cell Lymphoma. FEBS Lett. 2005, 579, 6885-6889.
12. (b) Herrera, B.; Carracedo, A.; Diez-Zaera, M.; Guzman, M.; Velasco, G. p38 Mapk Is Involved in CB2 Receptor-Induced Apoptosis of Human Leukaemia Cells. FEBS Lett. 2005, 579, 5084-5088.
13. (a) Pryce, G.; Baker, D. Emerging Properties of Cannabinoid Medicines in Management of Multiple Sclerosis. Trends Neurosci. 2005, 28, 272-276.
14. 2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis. J. Neurosci. 2007, 27, 2396-2402.
15. (c) Baker, D.; Pryce, G.; Croxford, J. L.; Brown, P.; Pertwee, R. G.; Huffman, J. W.; Layward, L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404, 84-87.
16. 2, Regulates Bone mass. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 696-701.
17. 2 Receptors and Fatty Acid Amide Hydrolase are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains. J. Neurosci. 2003, 23, 11136-11141.
18. 2 in the Liver. Gastroenterology 2005, 128, 742-755.
19. (b) Bátkai, S.; Osei-Hyiaman; Pan, H.; el-Assal, O.; Rajesh, M.; Mukhopadhyoy, P.; Hong, F.; Harvey-White, J.; Jafri, A.; Haskó, G.; Huffman, J. W.; Gao, B.; Kunos, G.; Pacher, P. Cannabinoid-2 Receptor Mediates Protection against Hepatic Ischemia/Reperfusion Injury. FASEB J. 2007, 21, 1788-1800.
20. 2 Receptors in Glucose Homeostasis in Rats. Eur. J. Pharmacol. 2007, 565, 207-211.
21. Huffman, J. W.; Padgett, L. W. Recent Development in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Curr. Med. Chem. 2005, 72, 1395-1411.
22. Bell, M. R.; D'Ambra, T. E.; Kumar, V.; Eissenstat, M. A.; Herrmann, J. L., Jr.; Wetzel, J. R.; Rosi, D.; Philion, R. E.; Daum, S. J.; Hlasta, D. J.; Kullnig, R. K.; Ackerman, J. H.; Haubrich, D. R.; Luttinger, D. A.; Baizman, E. R.; Miller, M. S.; Ward, S. J. Antinociceptive (Aminoalkyl)indole. J. Med. Chem. 1991, 34, 1099-1110.
23. D'Ambra, T. E.; Estep, K. G.; Bell, M. A.; Eissenstat, M. A.; Josef, K. A.; Ward, S. J.; Haycock, D. A.; Baizman, E. R.; Casiano, F. M.; Beglin, N. C.; Chippari, S. M.; Grego, J. D.; Kullnig, R. K.; Daley, G. T. Conformationally Restrained Analogues of Pravadoline: Nanomolar Potent, Enantioselective, (Aminoalkyl)indole Agonists of the Cannabinoid Receptor. J. Med. Chem. 1992, 35, 124-135.
24. Eissenstat, M. A.; Bell, M. R.; D'Ambra, T. E.; John, A. E.; Daum, S. J.; Ackerman, J. H.; Gruett, M. D.; Kumar, V.; Estep, K. G.; Olefirowicz, E. M.; Wetzel, J. R.; Alexander, M. D.; Weaver, J. D.; Haycock, D. A.; Luttinger, D. A.; Casiano, F. M.; Chippari, S. M.; Kuster, J. E.; Stevenson, J. I.; Ward, S. J. Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics. J. Med. Chem. 1995, 38, 3094-3105.
25. (a) Huffman, J. W.; Dai, D.; Martin, B. R.; Compton, D. R. Design, Synthesis and Pharmacology of Cannabimimetic Indoles. Bioorg. Med. Chem. Lett. 1994, 4, 563-566.
26. 2 Receptor Agonists. Bioorg. Med. Chem. 2005, 13, 89-112.
27. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001, 93, 239-245.
28. 2 Cannabinoid Receptors by AM1241 Inhibits Experimental Neuropathic Pain: Pain Inhibition by Receptors Not Present in the CNS. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10529-10533.
29. (c) Makriyannis, A.; Deng, H. U.S. Patent 7,173,027, 2007.
30. Malan, T. P., Jr.; Ibrahim, M. M.; Deng, H.; Liu, Q.; Mata, H. P.; Vanderah, T.; Porreca, F.; Makriyannis, A. CB2 Cannabinoid Receptor-Mediated Peripheral Antinociception. Pain 2001, 93, 239-245.
31. Ibrahim, M. M.; Porreca, F.; Lai, J.; Albrecht, P. J.; Rice, F. L.; Khodorova, A.; Davar, G.; Makriyannis, A.; Vanderah, T. W.; Mata, H. P.; Malan, T. P., Jr. CB2 Cannabinoid Receptor Activation Produces Antinociception by Stimulating Peripheral Release of Endogenous Opiods. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3093-3098.
32. 2-Selective Agonist, GW405833. Eur. J. Pharmacol. 2005, 528, 65-72.
33. 2 Receptor? Br. J. Pharmacol. 2006, 149, 145-154.
34. 2) Selective Ligand AM 1241 and Its Resolved Enantiomers. Br. J. Pharmacol. 2007, 151, 1061-1070.
35. (a) Gallant, M.; Dufresne, C.; Gareau, Y.; Guay, D.; Leblanc, Y.; Prasit, P.; Rochette, C.; Sawyer, N.; Slipefz, D. M.; Tremblay, N.; Metters, K. M.; Labelle, M. New Class of Potent Ligands for the Human Peripheral Cannabinoid Receptor. Bioorg. Med. Chem. Lett. 1996, 9, 2263-2268.
36. (b) Gallant, M.; Gareau, Y.; Guay, D.; Labelle, M.; Prasit, P. U.S. Patent 5,532,237, 1996.
37. (c) Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulet, J. M.; Gottshall, S. L.; Mark, L.; Pearson, M. S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Elsemore, D. A.; Toth, M.; Koetzner, L.; Whiteside, G. T. Pharmacological and Pharmacokinetic Characterization of the Cannabinoid Receptor 2 Agonist, GW405833, Utilizing Rodent Models of Acute and Chronic Pain, Anxiety, Ataxia and Catalepsy. Neuropharmacology 2005, 48, 658-672.
38. (a) Hynes, J., Jr; Leftheris, K.; Wu, H.; Pandit, C.; Chen, P.; Norris, D. J.; Chen, B.-C.; Zhao, R.; Kiener, P. A.; Chen, X.; Turk, L. A.; Patil-Koota, V.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W. C-3 Amido-Indole Cannabinoid Receptor Modulators. Bioorg. Med. Chem. Lett. 2002, 12, 2399-2402.
39. (b) Leftheris, K.; Zhao, R.; Chen, B-C.; Kiener, P.; Wu, H.; Pandit, C. R.; Wrobleski, S.; Chen, P.; Hynes, J., Jr; Longphre, M.; Norris, D. J.; Spergel, S.; Tokarski, J. U.S. Patent 6,653,304, 2003.
40. Wrobleski, S.; Chen, P.; Hynes, J., Jr.; Lin, S.; Norris, D. J.; Pandit, C. R.; Spergel, S.; Wu, H.; Tokarski, J.; Chen, X.; Gillooly, K. M.; Kiener, P. A.; McIntyre, K. W.; Patil-koota, V.; Shuster, D. J.; Turk, L. A.; Yang, G.; Leftheris, K. Rational Design and Synthesis of an Orally Active Indolopyridone as a Novel Conformationally Constrained Cannabinoid Ligand Possessing Antiinflammatory Properties. J. Med. Chem. 2003, 46, 2110-2116.
41. Ratcliffe, P. D.; Adam-Worrall, J.; Morrison, A. J.; Francis, S. J.; Kiyoi, T. Patent Application WO2007/023143, 2007.
42. Bleicher, K.; Nettekoven, M. H.; Pflieger, P.; Roever, S. U.S. Patent Application 2006/0089367, 2006.
43. (a) Eatheron, A. J.; Giblin, G. M. P.; Johnson, M. R.; Mitchell, W. L.; Perboni, A.; Slingsby, B. P. Patent Application WO05/121140, 2005.
44. (b) Eatheron, A. J.; Giblin, G. M. P.; Jandu, K. S.; Johnson, M. R.; Mitchell, W. L.; Naylor, A.; Sweeting, J. A. Patent Application WO07/017264, 2007.
45. Barth, F.; Guillaumont, C.; Rinaldi-Carmona, M.; Vernhet, C. U.S. Patent 7,138,424, 2006.
46. Shankar, B. B.; Gilbert, E.; Rizvi, R. K.; Huang, C.; Kozlowski, J. A.; McCombie, S.; Shih, N. Y. Patent Application WO06/002133, 2006.
47. Pace, J. M.; Tietje, K. R.; Dart, M. J.; Meyer, M. D. Patent Application WO06/069196, 2006.
48. Bergman, J.; Venemalm, L. Acylation of the Zinc Salt of Indole. Tetrahedron 1990, 46, 6061-6066.
49. 56 (CP 55,940) is (-)-cis-3-[2-Hydroxy-4-(1,1- dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol and was obtained from Tocris Bioscience.
50. 2 cannabinoid receptors. Eur. J. Pharmacol. 2004, 505, 1-9.
51. 22
52. 22
53. 2 Receptor Agonist Exhibiting Analgesic Activity in Rodent Pain Models Br. J. Pharmacol. 2008, 153, 390-401.
54. Hargreaves, K.; Dubner, R.; Brown, F.; Flores, C.; Joris, J. A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia. Pain 1988, 32, 77-88.